| [1] |
Contractor KB, Kaur K, Rodrigues GS, et al. Male breast cancer: is the scenario changing[J]. World J Surg Oncol, 2008，6：58.
|
| [2] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
|
| [3] |
Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline[J]. J Clin Oncol, 2020，38(16)：1849-1863.
|
| [4] |
申戈，宋三泰，江泽飞，等. 睾丸切除加来曲唑治疗晚期男性乳腺癌一例[J]. 中华医学杂志，2004, 84(3)：29.
|
| [5] |
Eggemann H, Altmann U, Costa SD, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients[J]. Breast Cancer Res Treat，2013，137(2)：465-470.
|
| [6] |
Mauras N, O’Brien KO, Klein KO, et al. Estrogen suppression in males: metabolic effects[J]. J Clin Endocrinol Metab, 2000, 85(7)：2370-2377.
|
| [7] |
Bighin C, Lunardi G, Del Mastro L, et al. Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors[J]. Oncologist, 2010, 15(12)：1270-1272.
|
| [8] |
Zagouri F, Sergentanis TN, Azim HA Jr, et al. Aromatase inhibitors in male breast cancer：a pooled analysis[J]. Breast Cancer Res Treat, 2015, 151(1)：141-147.
|
| [9] |
国家肿瘤质控中心乳腺癌专家委员会，中国抗癌协会乳腺癌专业委员会，中国抗癌协会肿瘤药物临床研究专业委员会．中国晚期乳腺癌规范诊疗指南(2020版)[J]. 中华肿瘤杂志，2020，42(10)：781-797.
|
| [10] |
U．S. Food and Drug Administration. U．S. FDA approves IBRANCE? (palbociclib) for the treatment of men with HR+，HER2- metastatic breast cancer[EB/OL]．[2022-11-01]．
URL
|
| [11] |
Morisseau C, Pakhomova S, Hwang SH, et al. Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides[J]. Bioorg Med Chem Lett, 2013, 23(13)：3818-3821.
|
| [12] |
Zagouri F, Sergentanis TN, Chrysikos D, et al. Fulvestrant and male breast cancer: a pooled analysis[J]. Breast Cancer Res Treat, 2015, 149(1)：269-275.
|
| [13] |
Hansra D, Jackson S, Sequeira J, et al. Male patient with metastatic stage breast cancer chieves complete remission on second line abemaciclib, fulvestrant and leuprolide: a case report[J]. Mol Clin Oncol, 2020, 12(2)：120-125.
|
| [14] |
Tripathy D, Blum JL, Rocque GB, et al. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor positive advanced breast cancer[J]. Future Oncol, 2020, 16(31)：2475-2485.
|